We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Canadian health officials have launched a public consultation on restricting supplies of bulk drugs to the US, in the event that a possible liberalisation of cross-border trade creates shortages in Canada.
As part of France's increasingly desperate efforts to curb healthcare spending, the government is to introduce a 2.2% limit on healthcare reimbursement growth for the period 20072009.
Indian generics firms claim to have filed over 143 Drug Master Files (DMFs) with the US FDA in the first half of 2005, equivalent to 35% of all DMFs registered in the period.
The directors of Specpharm and Westbury -- which at the end of October become subsidiaries of AltX-listed Enaleni -- say they will defend in court their right to distribute Indian drug maker Lupin's products in South Africa should it come to that.
Vasogen Inc. (NASDAQ:VSGN -- News; TSX:VAS -- News), today announced that its wholly-owned Irish subsidiary, Vasogen Ireland Limited ("Vasogen Ireland"), has signed definitive agreements to close a private placement of US$40 million senior convertible notes to several institutional investors.
Glenmark Pharmaceuticals SA filed for Phase I clinical trials for its leading DPP-IV inhibitor compound, GRC 8200 with Medicines and Healthcare Products Regulatory Agency (MHRA) in UK.
Altana AG's chief executive Nikolaus Schweickart told the Boersen-Zeitung the company sees autumn, 2006 as a likely date for the spin off of its chemical division.
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)("Oncolytics") announced today it has been granted Canadian Patent 2,428,206 entitled "Methods for the treatment of cellular proliferative disorders."